Volume 42, number 1: Culture of Percutaneous Bone Biopsy Specimens for Diagnosis of Diabetic Foot Osteomyelitis: Concordance with Ulcer Swab Cultures
2nd Dec 2005, 23:36 GMT
Background. We assessed the diagnostic value of swab cultures by comparing them with corresponding cultures of percutaneous bone biopsy specimens for patients with diabetic foot osteomyelitis. Methods. The medical charts of patients with foot osteomyelitis who underwent a surgical percutaneous bone biopsy between January 1996 and June 2004 in a single diabetic foot clinic were reviewed. Seventy-six patients with 81 episodes of foot osteomyelitis who had positive results of culture of bone biopsy specimens and who had received no antibiotic therapy for at least 4 weeks before biopsy constituted the study population. Results. Pathogens isolated from bone samples were predominantly staphylococci (52%) and gram-negative bacilli (18.4%). The distributions of microorganisms in bone and swab cultures were similar, except for coagulase-negative staphylococci, which were more prevalent in bone samples ([FORMULA]). The results for cultures of concomitant foot ulcer swabs were available for 69 of 76 patients. The results of bone and swab cultures were identical for 12 (17.4%) of 69 patients, and bone bacteria were isolated from the corresponding swab culture in 21 (30.4%) of 69 patients. The concordance between the results of cultures of swab and of bone biopsy specimens was 42.8% for Staphylococcus aureus, 28.5% for gram-negative bacilli, and 25.8% for streptococci. The overall concordance for all isolates was 22.5%. No adverse events—such as worsening peripheral vascular disease, fracture, or biopsy-induced bone infection—were observed, but 1 patient experienced an episode of acute Charcot osteoarthropathy 4 weeks after bone biopsy was performed. Conclusions. These results suggest that superficial swab cultures do not reliably identify bone bacteria. Percutaneous bone biopsy seems to be safe for patients with diabetic foot osteomyelitis.
Volume 42, number 1: Culture of Percutaneous Bone Biopsy Specimens for Diagnosis of Diabetic Foot Osteomyelitis: Concordance with Ulcer Swab Cultures related news:
- Volume 42, number 1: Microbiological Evaluation of Diabetic Foot Osteomyelitis — Clin Infect Dis Latest Issue
- Volume 42, number 1: Validation and Clinical Application of Molecular Methods for the Identification of Molds in Tissue — Clin Infect Dis Latest Issue
- Custom and Synthetic (Windows ELK) RegionInfos in .Net 2.0 — Shawn Steele's Blog
- Entwicklung des ersten verletzungsfrei arbeitenden Blutzuckermessgerätes schreitet voran / Diabetic Trust KG von Beschluss der Bundesregierung zu Steuer-Fonds nicht betroffen — Presseportal.de Wirtschaft
- Volume 42, number 1: Bone Disease and HIV Infection — Clin Infect Dis Latest Issue
- Algeria president has surgery for ulcer — KeralaNext: Middle East
- 528,86% Rendite mit schmerzfreier Blutzuckermessung / BaFin erteilt Genehmigung von Verkaufsprospekt — Presseportal.de Finanzen
- Lidocaine suppositories curb prostate biopsy pain (Reuters) —
- Klingon Custom Culture/Locale MS LDML File — Shawn Steele's Blog
- Healing Feet with Retin-A — ConsumerAffairs.Com News
Latest news from Clin Infect Dis Latest Issue:
- Volume 43, number S4: Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment
- Volume 43, number S4: Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
- Volume 43, number S4: The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
- Volume 43, number S4: A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
- Volume 43, number S4: Initial Strategies for Integrating Buprenorphine into HIV Care Settings in the United States
- Volume 43, number S4: Buprenorphine Use: The International Experience
- Volume 43, number S4: Pharmacokinetic Interactions between Buprenorphine and Antiretroviral Medications
- Volume 43, number S4: Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
- Volume 43, number S4: Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir
- Volume 43, number S4: Overcoming Policy and Financing Barriers to Integrated Buprenorphine and HIV Primary Care